These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 28720082)

  • 1. Cost-effectiveness analysis of different types of human papillomavirus vaccination combined with a cervical cancer screening program in mainland China.
    Mo X; Gai Tobe R; Wang L; Liu X; Wu B; Luo H; Nagata C; Mori R; Nakayama T
    BMC Infect Dis; 2017 Jul; 17(1):502. PubMed ID: 28720082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cost-utility analysis of cervical cancer screening and human papillomavirus vaccination in the Philippines.
    Guerrero AM; Genuino AJ; Santillan M; Praditsitthikorn N; Chantarastapornchit V; Teerawattananon Y; Alejandria M; Toral JA
    BMC Public Health; 2015 Jul; 15():730. PubMed ID: 26223975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N; Van Kriekinge G; Simon P
    Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of policy options for prevention and control of cervical cancer in Thailand.
    Praditsitthikorn N; Teerawattananon Y; Tantivess S; Limwattananon S; Riewpaiboon A; Chichareon S; Ieumwananonthachai N; Tangcharoensathien V
    Pharmacoeconomics; 2011 Sep; 29(9):781-806. PubMed ID: 21838332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis.
    Zou Z; Fairley CK; Ong JJ; Hocking J; Canfell K; Ma X; Chow EPF; Xu X; Zhang L; Zhuang G
    Lancet Glob Health; 2020 Oct; 8(10):e1335-e1344. PubMed ID: 32971056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in Adolescent Girls in Taiwan.
    Tang CH; Cheng WF; Jiang JH; You SL; Huang LW; Hsieh JY; Mukherjee P; Van Kriekinge G; Lee C
    Asian Pac J Cancer Prev; 2019 May; 20(5):1377-1387. PubMed ID: 31127896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis.
    Simms KT; Laprise JF; Smith MA; Lew JB; Caruana M; Brisson M; Canfell K
    Lancet Public Health; 2016 Dec; 1(2):e66-e75. PubMed ID: 29253419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of human papillomavirus vaccination and screening in Spain.
    Diaz M; de Sanjose S; Ortendahl J; O'Shea M; Goldie SJ; Bosch FX; Kim JJ
    Eur J Cancer; 2010 Nov; 46(16):2973-85. PubMed ID: 20638840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
    Gomez JA; Lepetic A; Demarteau N
    BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
    Armstrong EP
    J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination.
    Chen MK; Hung HF; Duffy S; Yen AM; Chen HH
    J Eval Clin Pract; 2011 Dec; 17(6):1050-8. PubMed ID: 21679279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program.
    Kulasingam S; Connelly L; Conway E; Hocking JS; Myers E; Regan DG; Roder D; Ross J; Wain G
    Sex Health; 2007 Sep; 4(3):165-75. PubMed ID: 17931529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland.
    Szucs TD; Largeron N; Dedes KJ; Rafia R; Bénard S
    Curr Med Res Opin; 2008 May; 24(5):1473-83. PubMed ID: 18413014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of two-dose human papillomavirus vaccination in Singapore.
    Tay SK; Lee BW; Sohn WY; Lee IH; Mathur G; Sanicas M; Van Kriekinge G
    Singapore Med J; 2018 Jul; 59(7):370-382. PubMed ID: 28983579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of HPV vaccination in the prevention of cervical cancer in Malaysia.
    Ezat WP; Aljunid S
    Asian Pac J Cancer Prev; 2010; 11(1):79-90. PubMed ID: 20593935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneously characterizing the comparative economics of routine female adolescent nonavalent human papillomavirus (HPV) vaccination and assortativity of sexual mixing in Hong Kong Chinese: a modeling analysis.
    Choi HCW; Jit M; Leung GM; Tsui KL; Wu JT
    BMC Med; 2018 Aug; 16(1):127. PubMed ID: 30115065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India.
    Diaz M; Kim JJ; Albero G; de Sanjosé S; Clifford G; Bosch FX; Goldie SJ
    Br J Cancer; 2008 Jul; 99(2):230-8. PubMed ID: 18612311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative cost-effectiveness of HPV vaccines in the prevention of cervical cancer in Malaysia.
    Ezat SW; Aljunid S
    Asian Pac J Cancer Prev; 2010; 11(4):943-51. PubMed ID: 21133606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
    Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
    Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.